Lipoprotein(a), TMAO, and Gut Dysbiosis Linked to Heart Disease, Unrelated to Fatty Liver
New research indicates that elevated levels of lipoprotein(a) [Lp(a)], trimethylamine n-oxide (TMAO), and gut dysbiosis are independently associated with subclinical coronary atherosclerosis. This finding holds true even when metabolic dysfunction-associated steatotic liver disease (MASLD) is not present. The study highlights these factors as significant contributors to the early stages of heart disease, separate from the impact of MASLD. Subclinical coronary atherosclerosis refers to the buildup of plaque in the arteries that does not yet cause noticeable symptoms. Lp(a) is a type of cholesterol that is genetically determined and known to increase cardiovascular risk. TMAO is a compound produced by gut bacteria when they metabolize certain nutrients, and high levels have been linked to heart disease. Gut dysbiosis signifies an imbalance in the gut's microbial community, which can affect various bodily functions, including cardiovascular health. The research suggests that addressing these specific biomarkers may be crucial for preventing or managing coronary artery disease, regardless of a patient's liver health status concerning MASLD. This distinction is important for understanding the multifactorial nature of atherosclerosis and for developing targeted prevention and treatment strategies.
This study delineates distinct pathways contributing to subclinical coronary atherosclerosis, separating the influence of lipoprotein(a), trimethylamine n-oxide, and gut dysbiosis from metabolic dysfunction-associated steatotic liver disease. Such a distinction is vital for refining risk stratification models, potentially enabling more precise interventions. Future research could explore the synergistic effects of these factors and their implications for personalized medicine, particularly in the context of evolving diagnostic criteria and therapeutic targets for cardiovascular and metabolic diseases. Understanding these independent associations may also inform public health strategies aimed at mitigating cardiovascular risk across diverse populations.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.
